Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

Taysha Gene Therapies Inc.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on HeartFlow, Inc. (HTFL), Taysha Gene Therapies (TSHA)...

Analysts Are Bullish on These Healthcare Stocks: HeartFlow, Inc. (HTFL), Taysha Gene Therapies (TSHA)

Wells Fargo analyst Yanan Zhu maintained a Buy rating on Taysha Gene Therapies on March 20 and set a price target of $11.00. The company’s shares c...

Taysha Gene Therapies (TSHA) Receives a Buy from Wells Fargo

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Taysha Gene Therapies (TSHA) and Fulcrum Therapeutic...

Analysts Offer Insights on Healthcare Companies: Taysha Gene Therapies (TSHA) and Fulcrum Therapeutics (FULC)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Collegium Pharmaceutical (COLL) and Taysha Gene Ther...

Analysts Are Bullish on These Healthcare Stocks: Collegium Pharmaceutical (COLL), Taysha Gene Therapies (TSHA)

Chardan Capital analyst Geulah Livshits maintained a Buy rating on Taysha Gene Therapies today and set a price target of $12.00. According to TipRa...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Record Date	N/A	Declaration	N/A
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	TSHA	$4.55	-0.55%	953.43K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	TSHA	$4.55	-0.5%	953.43K
3
4
5
6

TSHA

TSHA

Dividend Overview

Get Taysha Gene Therapies Inc. Data in Excel

Get Taysha Gene Therapies Inc. Data in Excel